
- /
- Supported exchanges
- / US
- / AZNCF.PINK
AstraZeneca PLC (AZNCF PINK) stock market data APIs
AstraZeneca PLC Financial Data Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get AstraZeneca PLC data using free add-ons & libraries
Get AstraZeneca PLC Fundamental Data
AstraZeneca PLC Fundamental data includes:
- Net Revenue: 54 073 M
- EBITDA: 17 567 M
- Earnings Per Share: 4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-29
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AstraZeneca PLC News

The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
For Immediate Release Chicago, IL – April 25, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and ...


Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca
Earnings season is now in full swing, with a number of key companies due to report in the coming week, including four of the Magnificent 7 tech giants in focus. Uncertainty over US president Donald T...

Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN and Pathos AI. The multi-year deal focuses on building a multimodal AI-drive...

Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics
In its upcoming report, Astrazeneca (AZN) is predicted by Wall Street analysts to post quarterly earnings of $1.10 per share, reflecting an increase of 6.8% compared to the same period last year. Reve...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.